SCHEMBL1317147

SCHEMBL1317147

CCOc1ccc(OC(C)=O)c(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.61
KDM4E B2RXH2 8/20 0.56
HSD17B10 Q99714 5/20 0.51
TSHR P16473 5/20 0.51
ALDH1A1 P00352 3/20 0.51
PTGS1 P23219 2/20 0.51
PTGS2 P35354 2/20 0.51
HPGD P15428 2/20 0.51
ESR1 P03372 1/20 0.51
ITGB3 P05106 1/20 0.51
ITGA2B P08514 1/20 0.51
HMGB1 P09429 1/20 0.51
GGT1 P19440 1/20 0.51
BLM P54132 1/20 0.51
NAPRT Q6XQN6 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
CYP1A2 P05177 2/20 0.49
LMNA P02545 3/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1319189 0.88 CFD (0.58) CFDKDM4EHSD17B10TSHRALDH1A1
SCHEMBL1107710 0.87 KDM4E (0.63) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL344505 0.85 KDM4E (0.74) CFDKDM4EHSD17B10TSHRALDH1A1
SCHEMBL1318999 0.82 CFD (0.67) CFDKDM4EHSD17B10TSHRALDH1A1
SCHEMBL181472 0.81 KDM4E (0.51) KDM4ETSHRALDH1A1TDP1CYP1A2
SCHEMBL12166002 0.81 KDM4E (0.51) KDM4ETSHRALDH1A1TDP1CYP1A2
SCHEMBL930228 0.80 ALDH1A1 (0.59) KDM4EHSD17B10TSHRALDH1A1HPGD
SCHEMBL6908590 0.79 KDM4E (0.76) CFDKDM4EHSD17B10TSHRALDH1A1
SCHEMBL1316323 0.79 ALDH1A1 (0.65) CFDKDM4EHSD17B10TSHRALDH1A1
SCHEMBL12121006 0.79 KDM4E (0.56) CFDKDM4EALDH1A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 CFD 2776/4885KDM4E 1141/4885HSD17B10 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.